New York (ots/PRNewswire) - Corsearch enhances its market-leading brand protection solution through the acquisition of the anti-piracy innovator, Marketly. The acquisition will support businesses with a total brand protection solution that protects brands, reputation, and content. Corsearch, Inc. is pleased to announce the acquisition of the prominent provider of anti-piracy services, Marketly. The acquisition strengthens ...
New York (ots/PRNewswire) - ACG Analytics, an independent policy research firm based in Washington, D.C., in partnership with Makor Oscar Gruss, an international agency brokerage group trading cash equities, fixed income, FX and derivative products, is pleased to announce a collaboration to provide clients with an analysis of the impact of public policy on capital markets. "I'm excited to bring our trusted analytical ...
New York (ots/PRNewswire) - Enigma Securities Ltd. (www.enigma-securities.io), a technology-driven financial institution dedicated to corporate client solutions for cryptoassets, announced today the partnership with Iconic Holding's Multi-Manager Platform (www.iconicholding.com). Applying its expertise in capital markets, Enigma will provide liquidity, provision of ...
New York (ots/PRNewswire) - Enigma Securities (www.enigma-securities.io), a crypto-focused financial institution specialized in electronic execution services is expanding its compliance and security protocols to include advanced blockchain forensics through a recent partnership with Elementus (www.elementus.io). ...
New York (ots/PRNewswire) - Enigma Securities (www.enigma-securities.io), a crypto-focused financial institution, specialized in electronic execution services announced today the expansion of its services to provide access for Bitcoin Futures and Options block trading, through a new partnership with CME Group ...
New York (ots/PRNewswire) - Enigma Securities (www.enigma-securities.io), a crypto liquidity provider focused on electronic execution services, announced today its new partnership with Fireblocks (www.fireblocks.com) and its joining of the recently launched Asset Transfer Network. By leveraging Fireblocks' secure Asset Transfer Network, Enigma can safely and securely ...
Darmstadt, Germany and New York (ots/PRNewswire) - - Not intended for US-, Canada- or UK-based media - ASCO Abstract # BAVENCIO® (avelumab): LBA1, 5061; Bintrafusp alfa (bifunctional fusion protein): 9558; Tepotinib (MET kinase inhibitor): 9556, 9575. - Late-breaking presentation of Phase III JAVELIN Bladder 100 data for BAVENCIO® showing overall survival benefit in ...
New York (ots/PRNewswire) - Decisive action is now needed to fight the coronavirus successfully. Most importantly, nursing staff needs protection and support. Everything that makes their work easier improves patient care, relieves pressure on hospitals and, in the end, helps saving lives. That is why ClinicAll developed the new ClinicAll Communicator app. It connects patients and staff in the simplest way - digital, ...
BMO Financial Group - Acquisitions
New York and Toronto (ots/PRNewswire) - - Fintech acquisition delivers modern, cloud-based electronic trading platform with visual data analytics and customizable algorithmic strategies - Emphasizes BMO's priorities to provide innovative technology to clients and expand in areas of opportunity and strength - BMO Financial Group (NYSE, TSX: BMO) today announced that it has entered into a definitive agreement to acquire ...
New York (ots/PRNewswire) - ClinicAll International Corporation is excited to announce the strategic partnership with The Private Office of Sheikh Saeed Bin Ahmed Al Maktoum and SEED Group. On 8th October 2019, Hisham Al Gurg, CEO of The Private Office of Sheikh Saeed Bin Ahmed Al Maktoum and the SEED Group, and ...
Not intended for US, Canada and UK-based media -- EU approval based on JAVELIN Renal 101 trial results demonstrating significant improvement in progression-free survival with BAVENCIO in combination with axitinib compared with sunitinib -- Combination regimen approved across all IMDC prognostic risk groups and ...
Not intended for US, Canada and UK-based media Darmstadt, Germany, and New York (ots/PRNewswire) - Merck and Pfizer Inc. (NYSE: PFE) today announced the presentation of multiple analyses from the JAVELIN clinical development program assessing BAVENCIO® (avelumab) alone or as part of combination regimens for the ...
Not intended for US, Canada and UK-based media - Opinion based on Phase III data showing combination lowered risk of disease progression or death by 31% and improved objective response rate compared with sunitinib1 - Decision by the European Commission anticipated in fourth quarter of 2019 Darmstadt, Germany and ...
Caisse de dépôt et placement du Québec
Montreal and New York (ots/PRNewswire) - The CREO Family Office Syndicate (CREO), a not-for-profit global network of family offices headquartered in New York City, and Caisse de dépôt et placement du Québec (CDPQ), a leading long-term institutional investor, today announced a new partnership to foster more capital into climate investments by creating new opportunities, sharing expertise and exercising stronger climate ...
Not intended for US, Canada and UK-based media Darmstadt, Germany and New York (ots/PRNewswire) - Merck and Pfizer Inc. (NYSE: PFE) today announced the discontinuation of the ongoing Phase III JAVELIN Ovarian PARP 100 study evaluating the efficacy and safety of avelumab in combination with chemotherapy followed by ...
Not intended for US, Canada and UK-based media Darmstadt, Germany and New York (ots/PRNewswire) - - JAVELIN Renal 101 shows significant improvement in progression-free survival with a hazard ratio of 0.69 in patients regardless of PD-L1 expression - US FDA has granted Priority Review to BAVENCIO plus INLYTA for ...
Darmstadt, Germany and New York (ots/PRNewswire) - Not intended for US, Canada and UK-based media Merck and Pfizer Inc. (NYSE: PFE) today announced that the US Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for BAVENCIO® (avelumab) in ...
Darmstadt, Germany and New York (ots/PRNewswire) - Not intended for US, Canada and UK-based media Merck and Pfizer Inc. (NYSE: PFE) today announced that data from a planned interim analysis of the Phase III JAVELIN Ovarian 100 study of avelumab* did not support the study's initial hypothesis, and therefore the ...
Darmstadt, Germany and New York (ots/PRNewswire) - Not intended for US, Canada and UK-based media Merck and Pfizer Inc. (NYSE: PFE) today announced that the Phase III JAVELIN Ovarian 200 trial evaluating avelumab* alone or in combination with pegylated liposomal doxorubicin (PLD), a type of chemotherapy, compared ...
New York and Luxembourg (ots/PRNewswire) - New Funding Round, Led By AccorHotels, To Accelerate The Development Of Services Leveraging Travelsify's Hotel DNA(TM) and Restaurant DNA(TM) AI Technology Travelsify (http://www.travelsify.com/), the world's first Travel & Lifestyle Product DNA platform, today announced ...
Darmstadt, Germany and New York (ots/PRNewswire) - Not intended for US, Canada and UK-based media - First positive Phase III immunotherapy trial in combination with a tyrosine kinase inhibitor (TKI) in any tumor type - Results significant in both PDL1+ and all-comer populations - Alliance plans to pursue a ...
World Innovation Summit for Education (WISE)
New York (ots/PRNewswire) - The World Innovation Summit for Education (WISE) (https://www.wise-qatar.org/), an initiative of Qatar Foundation, will be holding a one-day forum, on September 22nd, as part of the Global Goals Week, during the United Nations General Assembly. The event will take place at the Altman ...
Darmstadt, Germany and New York (ots/PRNewswire) - Not intended for UK-based media Merck and Pfizer Inc. (NYSE: PFE) today announced results from the Phase III JAVELIN Lung 200 trial comparing avelumab* to docetaxel in patients with unresectable, recurrent or metastatic non-small cell lung cancer (NSCLC) whose ...
Darmstadt, Germany and New York (ots/PRNewswire) - - Second Breakthrough Therapy Designation for avelumab in hard-to-treat cancer - Renal cell carcinoma, the most common form of kidney cancer, has a poor prognosis in advanced stage[1],[2] - Javelin Renal clinical development program is ongoing, including Phase III ...
Toronto and New York (ots/PRNewswire) - Scotiabank announced today partnerships with two prominent Israeli technology leaders, Viola Group and Team8. These partnerships further establish Scotiabank as a leader in the global innovation ecosystem and will help accelerate its development of technology capabilities, ...
Darmstadt, Germany and New York (ots/PRNewswire) - Not intended for UK-based media - Pivotal Phase III Javelin trial investigating avelumab as third-line treatment for patients with unresectable, recurrent or metastatic gastric cancer did not meet its pre-specified primary endpoint of superior overall survival ...
Darmstadt, Germany and New York (ots/PRNewswire) - Not intended for US, Canadian and UK-based media - First-ever treatment indicated for curatively unresectable Merkel cell carcinoma (MCC) and first anti-PD-L1 to be available in Japan - Japanese Ministry of Health, Labour and Welfare (MHLW) decision based on Javelin Merkel 200 study, the largest registrational trial for an immunotherapy in MCC - First Asian approval for ...
Darmstadt, Germany, and New York, Usa (ots/PRNewswire) - Not intended for US, Canadian and UK-based media - First approved immunotherapy for rare and aggressive skin cancer in the European Union, with initial launches planned in Germany and the UK - Builds on Bavencio's previous accelerated approvals in the US and recent approval in Switzerland - Approval is based on ...
Toronto, New York and London (ots/PRNewswire) - - Annual initiative has raised C$19.5 million since 2005, supporting more than 3,000 students - Program donates a day's worth of trading commissions generated by BMO Capital Markets in Canada, the U.S. and Europe BMO Capital Markets, the investment and corporate banking arm of BMO Financial Group (NYSE:BMO)(TSX:BMO), ...